Dr. John Cush RheumNow
1 year 10 months ago
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa
Dr. John Cush RheumNow
1 year 10 months ago
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos;… https://t.co/iaoykvKoCH https://t.co/e0pELS3hMu
Dr. John Cush RheumNow
1 year 10 months ago
ACR24 IL-17 Panel
Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u
A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.
Chronic pain is an acute and debilitating condition that affects millions of people worldwide. And while pain interventions are available, many people struggle without treatment at all.
Dr. John Cush RheumNow
1 year 10 months ago
Navigating Rheumatology Care in Humanitarian Crisis Settings
Dr. Antoni Chan talks with Dr. Martha Dhzhus, who presented Thursday at the Global Summit about rheumatology care in the Ukraine, at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/k4YTVFnTiF https://t.co/bScrJ28rKi
Dr. John Cush RheumNow
1 year 10 months ago
Metabolic syndrome assoc w/ with response rates in #RA (CDAI MCID OR 0.6), on or off TNFi. Adipokines were associated with metabolic syndrome but were not associated with clinical responses. Data from CERTAIN cohort & CorEvitas registry https://t.co/YH44iTwYTr https://t.co/ec3vb266ym
Dr. John Cush RheumNow
1 year 10 months ago
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).
Dr. John Cush RheumNow
1 year 10 months ago
Summary of JAKi Studies
Dr. Peter Nash, at the 2024 ACR Convergence meeting in Washington, DC, talks about JAKi data presented in: the SELECT-GCA trial and safety signals; ILD; cancer; cycling; RA; uveitis; and new JAKs under study.
https://t.co/ywmtrTi0iF https://t.co/nbFFojL1i4
Dr. John Cush RheumNow
1 year 10 months ago
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index… https://t.co/qyZPDzUduO https://t.co/cCoc3sWCJy
Dr. John Cush RheumNow
1 year 10 months ago
Infertility linked to post-childbrith onset of systemic autoimmune disease
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a… https://t.co/NJf44KJ2Hc https://t.co/W4rhsDHoqB
